1. Toll-Like Receptors in Acute Kidney Injury
- Author
-
Sandra Rayego-Mateos, Mercedes Vallejo-Mudarra, Isabel Cortegano, María Luisa Gaspar, Carmen Herencia-Bellido, Lucas Opazo-Ríos, Melania Guerrero-Hue, Cristina Vázquez-Carballo, José Luis Morgado-Pascual, Cristina García-Caballero, Juan Antonio Moreno, Belén de Andrés, Jesús Egido, [Vázquez-Carballo,C, Rayego-Mateos,S, Opazo-Ríos,L, Herencia-Bellido,C, Egido,J] Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain. [Guerrero-Hue,M, García-Caballero,C, Morgado-Pascual,JL, Vallejo-Mudarra,M, Moreno,JA] Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, Córdoba, Spain. [Opazo-Ríos,L, Egido,J] Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain. [Cortegano,I, Gaspar,ML, de Andrés,B] Immunobiology Department, Carlos III Health Institute, Majadahonda (Madrid), Spain. [Moreno,JA] Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Madrid, Spain. [Moreno,JA] Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain, The authors work has been supported by grants from Instituto de Salud Carlos III (ISCIII, FIS-FEDER PI17/00130, PI17/01495, PI20/00375, PI20/00487), Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM) and Cardiovascular (CIBERCV), Spanish Ministry of Science and Innovation (RTI2018-099114-B-100, RTI2018-098788-B-100, DTS19/00093, RYC-2017-22369), and Spanish Societies of Cardiology (SEC), Nephrology (SEN) and Atherosclerosis (SEA). The 'PFIS' and 'Sara Borrell' training program of the ISCIII supported the salary of MGH (FI18/00310), SR-M (CD19/00021) and CH-B (CP16/00017). Córdoba University supported the salary of C.G.C. No other relevant affiliations or financial involvement exist with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties., Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Sociedad Española de Cardiología, Sociedad Española de Nefrología, Sociedad Española de Arteriosclerosis, University of Córdoba (España), UAM. Departamento de Farmacología, UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), and Universidad de Córdoba
- Subjects
0301 basic medicine ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Pattern Recognition::Toll-Like Receptors::Toll-Like Receptor 4 [Medical Subject Headings] ,Anatomy::Urogenital System::Urinary Tract::Kidney [Medical Subject Headings] ,Nefrología y urología ,medicine.medical_treatment ,Diseases::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Acute Kidney Injury [Medical Subject Headings] ,Review ,Bioinformatics ,urologic and male genital diseases ,Kidney ,drugs ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings] ,Lesión renal aguda ,lcsh:Chemistry ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,0302 clinical medicine ,Risk Factors ,Chronic kidney disease ,Epidemiology ,Organisms::Eukaryota::Animals [Medical Subject Headings] ,Insuficiencia renal crónica ,Receptor ,lcsh:QH301-705.5 ,Spectroscopy ,Diseases::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency, Chronic [Medical Subject Headings] ,Toll-Like Receptors ,Acute kidney injury ,Drugs ,General Medicine ,Acute Kidney Injury ,female genital diseases and pregnancy complications ,Computer Science Applications ,Renal Replacement Therapy ,Terapia ,030220 oncology & carcinogenesis ,Disease Progression ,Medicamentos ,Persons::Persons::Patients::Survivors [Medical Subject Headings] ,medicine.symptom ,Factores de riesgo ,medicine.medical_specialty ,Medicina ,Receptores toll-like ,Inflammation ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Inflammatory Agents [Medical Subject Headings] ,Catalysis ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Renal Replacement Therapy [Medical Subject Headings] ,Inorganic Chemistry ,03 medical and health sciences ,Anthropology, Education, Sociology and Social Phenomena::Social Sciences::Internationality::International Cooperation::Developing Countries [Medical Subject Headings] ,medicine ,Animals ,Humans ,Renal replacement therapy ,Physical and Theoretical Chemistry ,Renal Insufficiency, Chronic ,Molecular Biology ,Pathological ,Diseases::Cardiovascular Diseases [Medical Subject Headings] ,therapy ,Inflamación ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression [Medical Subject Headings] ,business.industry ,urogenital system ,Organic Chemistry ,and therapy ,medicine.disease ,Toll-like receptors ,Toll-Like Receptor 4 ,030104 developmental biology ,lcsh:Biology (General) ,lcsh:QD1-999 ,Risk factors ,inflammation ,TLR4 ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Pattern Recognition::Toll-Like Receptors [Medical Subject Headings] ,Therapy ,business ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings] ,Kidney disease - Abstract
Acute kidney injury (AKI) is an important health problem, affecting 13.3 million individuals/year. It is associated with increased mortality, mainly in low- and middle-income countries, where renal replacement therapy is limited. Moreover, survivors show adverse long-term outcomes, including increased risk of developing recurrent AKI bouts, cardiovascular events, and chronic kidney disease. However, there are no specific treatments to decrease the adverse consequences of AKI. Epidemiological and preclinical studies show the pathological role of inflammation in AKI, not only at the acute phase but also in the progression to chronic kidney disease. Toll-like receptors (TLRs) are key regulators of the inflammatory response and have been associated to many cellular processes activated during AKI. For that reason, a number of anti-inflammatory agents targeting TLRs have been analyzed in preclinical studies to decrease renal damage during AKI. In this review, we updated recent knowledge about the role of TLRs, mainly TLR4, in the initiation and development of AKI as well as novel compounds targeting these molecules to diminish kidney injury associated to this pathological condition, The authors work has been supported by grants from Instituto de Salud Carlos III (ISCIII, FIS-FEDER PI17/00130, PI17/01495, PI20/00375, PI20/00487), Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM) and Cardiovascular (CIBERCV), Spanish Ministry of Science and Innovation (RTI2018-099114-B-100, RTI2018-098788-B-100, DTS19/00093, RYC-2017-22369), and Spanish Societies of Cardiology (SEC), Nephrology (SEN) and Atherosclerosis (SEA). The “PFIS” and “Sara Borrell” training program of the ISCIII supported the salary of MGH (FI18/00310), SR-M (CD19/00021) and CH-B (CP16/00017). Córdoba University supported the salary of C.G.C.
- Published
- 2021